The Liver Failure (Hepatic Insufficiency) drugs in development market research report provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Liver Failure (Hepatic Insufficiency). Buy the report here.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued products.
GlobalData tracks 46 drugs in development for Liver Failure (Hepatic Insufficiency) by 41 companies/universities/institutes. The top development phase for Liver Failure (Hepatic Insufficiency) is preclinical with 23 drugs in that stage. The Liver Failure (Hepatic Insufficiency) pipeline has 41 drugs in development by companies and five by universities/ institutes. Some of the companies in the Liver Failure (Hepatic Insufficiency) pipeline products market are: Genfit, Glycan Therapeutics and Shiftbio.
The key targets in the Liver Failure (Hepatic Insufficiency) pipeline products market include High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1), Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A), and Isocitrate Dehydrogenase [NADP] Mitochondrial (NADP(+)-Specific ICDH or Oxalosuccinate Decarboxylase or ICD M or IDP or IDH2 or EC 1.1.1.42).
The key mechanisms of action in the Liver Failure (Hepatic Insufficiency) pipeline product include High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) Inhibitor with two drugs in Preclinical. The Liver Failure (Hepatic Insufficiency) pipeline products include nine routes of administration with the top ROA being Intravenous and nine key molecule types in the Liver Failure (Hepatic Insufficiency) pipeline products market including Small Molecule, and Cell Therapy.
Liver Failure (Hepatic Insufficiency) overview
Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea, and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.
For a complete picture of Liver Failure (Hepatic Insufficiency)’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
